News from xencor, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-NMS:XNCR)

Feb 03, 2016, 08:00 ET

Xencor to Present at Two Upcoming Conferences in February

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jan 11, 2016, 08:00 ET

Xencor Announces Change to Board of Directors

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jan 07, 2016, 08:00 ET

National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Nov 24, 2015, 08:00 ET

Xencor to Present at Two Upcoming Conferences in December

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Nov 09, 2015, 08:00 ET

Xencor Presents Data on XmAb5871 Program at American College of Rheumatology (ACR) 2015 Annual Meeting

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Nov 05, 2015, 16:01 ET

Preclinical Data of Xencor's XmAb Bispecific Technology to be Presented at Upcoming ASH Annual Meeting

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Nov 04, 2015, 08:00 ET

Xencor to Present at Credit Suisse 24th Annual Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Nov 03, 2015, 16:01 ET

Xencor Reports Third Quarter 2015 Financial Results and Pipeline Update

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biotechnology company developing engineered monoclonal antibodies for the treatment of...

Oct 27, 2015, 08:00 ET

Xencor to Host Third Quarter 2015 Financial Results Webcast and Conference Call on November 3, 2015

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Sep 24, 2015, 16:01 ET

Xencor to Present at Leerink Partners Inaugural Immuno-Oncology Roundtable

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Sep 24, 2015, 08:00 ET

Xencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate Using XmAb® Cytotoxic Fc Domain

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Aug 04, 2015, 16:01 ET

Xencor Reports Second Quarter 2015 Financial and Operating Results

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Aug 04, 2015, 08:00 ET

Xencor to Present at 2015 Wedbush PacGrow Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

Jul 31, 2015, 08:00 ET

Xencor Appoints Yujiro S. Hata to Board of Directors

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jul 28, 2015, 08:00 ET

Xencor to Host Second Quarter 2015 Financial Results Webcast and Conference Call on August 4, 2015

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jun 26, 2015, 07:00 ET

Xencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of Bispecific Oncology Pipeline at R&D Day

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jun 12, 2015, 08:00 ET

Xencor to Host R&D Day and Webcast on June 26, 2015

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

Jun 10, 2015, 08:00 ET

Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...

May 26, 2015, 08:00 ET

Xencor to Present at Jefferies 2015 Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...

May 13, 2015, 08:00 ET

Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory Affairs and Wayne Saville, M.D., as Vice President of Clinical Oncology

 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of...